Table 1.
Detailed clinical characteristics of EOC patients enrolled in the gene expression profile, methylation profile and WES profile analyses.
| Characteristics | Expression profile+ | Methylation profile+ | Genetic profile+ |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
| Number of patients | 60 | 73 | 52 |
| Age (mean, years ± SD) | 60.1 ± 9.7 | 59.2 ± 9.7 | 59.7 ± 9.4 |
| Stage | |||
| I | 3 (5) | 3 (4.1) | 2 (3.8) |
| II | 3 (5) | 3 (4.1) | 3 (5.8) |
| III | 49 (81.7) | 62 (84.9) | 42 (80.8) |
| IV | 4 (6.6) | 4 (5.4) | 4 (7.7) |
| Not available | 1 (1.7) | 1 (1.5) | 1 (1.9) |
| EOC type | |||
| HGSC | 42 (70) | 54 (73.9) | 36 (69.3) |
| Others | 17 (28.3) | 18 (24.6) | 15 (28.8) |
| Not available | 1 (1.7) | 1 (1.5) | 1 (1.9) |
| Histological Grade | |||
| G1 | 5 (8.3) | 5 (6.8) | 5 (9.7) |
| G2 | 9 (15) | 10 (13.7) | 6 (11.5) |
| G3 | 46 (76.7) | 58 (79.5) | 41 (78.8) |
| Peritoneal Metastases | |||
| Present | 4 (6.7) | 4 (5.5) | 4 (7.7) |
| Absent | 54 (90) | 65 (89) | 47 (90.4) |
| Not available | 2 (3.3) | 4 (5.5) | 1 (1.9) |
| Residuum after surgery | |||
| Present | 33 (55) | 42 (57.5) | 28 (53.8) |
| Absent | 26 (43.3) | 31 (41) | 24 (46.2) |
| Not available | 1 (1.7) | 1 (1.5) | 0 (0) |
| Regimen of chemotherapy | |||
| Taxane with platinum derivatives1 | 57 (95) | 66 (90.4) | 50 (96.2) |
| Other regimens2 | 3 (5) | 6 (8.2) | 2 (3.8) |
| Unknown | 0 (0) | 1 (1.4) | 0 (0) |
| Platinum resistance status | |||
| Platinum-sensitive | 37 (61.6) | 43 (58.9) | 32 (61.5) |
| Platinum-resistant | 23 (38.4) | 30 (41.1) | 20 (34.5) |
| Platinum free interval (PFI) | |||
| All patients (mean ± SD; months) | 25 ± 25 | 22 ± 24 | 24 ± 25 |
| Sensitive patients (mean ± SD; months) | 38 ± 24 | 34 ± 24 | 37 ± 24 |
| Resistant patients (mean ± SD; months) | 4 ± 3 | 5 ± 3 | 4 ± 3 |
1 Regimen based on combination of paclitaxel with carboplatin/cisplatin.
2 Other regimen containing platinum monotherapy and combination of carboplatin +/- paclitaxel with Avastin.
+ All types of analyses were performed in 52 EOC patients. For gene expression (N=60) and methylation profiles (N=73), more samples of sufficient quality were available.